Skip to content

Effect of Aloe vera gel on acne vulgaris

Effect of Aloe vera topical gel combined with tretinoin in treatment of mild and moderate acne vulgaris: a randomized, double-blind, placebo controlled trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012070810203N2
Enrollment
60
Registered
2012-08-09
Start date
2010-04-03
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate acne vulgaris. acne vulgaris

Interventions

Intervention 1: Tretioin cream once a day (at night) and Aloe vera gel 50% (twice in day). Intervention 2: Tretinoin cream once a day (at night) and Placebo (twice in day) for 8 weeks.
Treatment - Drugs
Placebo
Tretioin cream once a day (at night) and Aloe vera gel 50% (twice in day)
Tretinoin cream once a day (at night) and Placebo (twice in day) for 8 weeks

Sponsors

Chancellor of Research, Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
11 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:the score of acne was determined based on GAGS scale and patients with mild to moderate acne vulgaris enter to study; and a urinary pregnancy test was performed; the cases have not received any medication. Exclusion criteria: Patients with an uncontrolled systemic disease; patients had received topical antiacne therapy two months before or during the study or any systemic therapy with antibiotics 30 days before or during the study; were known to be allergic or sensitive to any of the study medications or their components; had previously been treated with systemic retinoids; or were pregnant, or planning to become pregnant, and lactating.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Lesion count. Timepoint: 0, 2, 4, 8 th. week. Method of measurement: lesion scoring.;Adverse reactions (scaling, oedema, erythema, burning, and itching). Timepoint: 2, 4, 8 th. week. Method of measurement: observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Saeedi

Department of pharmaceutics

MSaeedi@mazums.ac.ir+98 15 1354 3082

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026